Duality Advisers LP Purchases 7,682 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Duality Advisers LP boosted its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 81.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 17,112 shares of the biopharmaceutical company's stock after purchasing an additional 7,682 shares during the quarter. Duality Advisers LP's holdings in Alnylam Pharmaceuticals were worth $3,275,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the business. Harbor Capital Advisors Inc. grew its holdings in Alnylam Pharmaceuticals by 1.8% during the 4th quarter. Harbor Capital Advisors Inc. now owns 2,938 shares of the biopharmaceutical company's stock worth $562,000 after acquiring an additional 51 shares in the last quarter. EP Wealth Advisors LLC grew its holdings in Alnylam Pharmaceuticals by 6.4% during the 3rd quarter. EP Wealth Advisors LLC now owns 1,177 shares of the biopharmaceutical company's stock worth $208,000 after acquiring an additional 71 shares in the last quarter. Oppenheimer & Co. Inc. grew its holdings in Alnylam Pharmaceuticals by 2.1% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 4,519 shares of the biopharmaceutical company's stock worth $800,000 after acquiring an additional 93 shares in the last quarter. Lindbrook Capital LLC grew its holdings in Alnylam Pharmaceuticals by 37.2% during the 4th quarter. Lindbrook Capital LLC now owns 369 shares of the biopharmaceutical company's stock worth $71,000 after acquiring an additional 100 shares in the last quarter. Finally, Xponance Inc. grew its holdings in Alnylam Pharmaceuticals by 0.7% during the 3rd quarter. Xponance Inc. now owns 14,984 shares of the biopharmaceutical company's stock worth $2,654,000 after acquiring an additional 109 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Needham & Company LLC restated a "buy" rating and issued a $200.00 price target on shares of Alnylam Pharmaceuticals in a report on Thursday, February 15th. Royal Bank of Canada restated an "outperform" rating and issued a $235.00 price target on shares of Alnylam Pharmaceuticals in a report on Tuesday, February 20th. StockNews.com cut shares of Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Sunday. HC Wainwright reaffirmed a "buy" rating and issued a $395.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Tuesday, March 5th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Alnylam Pharmaceuticals from $150.00 to $170.00 and gave the company a "neutral" rating in a research report on Thursday, February 1st. Nine investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $216.12.

Alnylam Pharmaceuticals Trading Up 1.0 %

NASDAQ ALNY traded up $1.38 during trading hours on Monday, reaching $145.79. The company had a trading volume of 399,984 shares, compared to its average volume of 792,052. The stock has a 50-day moving average of $151.09 and a 200 day moving average of $166.50. Alnylam Pharmaceuticals, Inc. has a 1-year low of $143.50 and a 1-year high of $218.88. The stock has a market capitalization of $18.36 billion, a P/E ratio of -40.95 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.20) by $0.10. The business had revenue of $439.72 million for the quarter, compared to analyst estimates of $439.38 million. The firm's revenue for the quarter was up 31.2% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.68) EPS. As a group, sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -4.54 EPS for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.